Rufomycin Targets ClpC1 Proteolysis in Mycobacterium tuberculosis and M. abscessus

Area of Science:

• Microbiology
• Biochemistry
• Drug Discovery

Background:

• ClpC1 is a validated target for treating Mycobacterium tuberculosis infections.
• Cyclic peptides like ecumicin, cyclomarin A, and lassomycin inhibit ClpC1.
• New therapeutic strategies targeting ClpC1 are needed.

Purpose of the Study:

• To identify novel peptide inhibitors of ClpC1.
• To characterize the mechanism of action of rufomycins (RUFs) against M. tuberculosis.
• To investigate the distinct binding and downstream effects of RUFI compared to other ClpC1 inhibitors.

Main Methods:

• Screening for bactericidal activity against M. tuberculosis.
• Determination of minimum inhibitory concentrations (MICs) for Rufomycin I (RUFI).
• Analysis of spontaneous RUFI-resistant mutants to identify mutations in clpC1.
• Assays to evaluate the effect of RUFI on ClpC1/P1/P2 complex proteolytic activity and ATPase activity.

Main Results:

• Rufomycins (RUFs) were identified as bactericidal against M. tuberculosis via ClpC1 inhibition.
• RUFI demonstrated potent and selective activity against M. tuberculosis (MIC, 0.02 μM) and M. abscessus (MIC, 0.4 μM).
• RUFI resistance emerged through mutations in the N-terminal domain of clpC1.
• RUFI significantly reduced ClpC1 complex proteolysis without affecting ATPase activity, differing from ecumicin's mechanism.

Conclusions:

• Rufomycins represent a novel class of bactericidal agents targeting ClpC1 in mycobacteria.
• RUFI is a promising lead compound for developing new anti-tubercular drugs.
• Distinct downstream effects of ClpC1 inhibitors highlight the complexity of targeting this essential protease.